TriSalus Life Sciences’ SD-101 yields positive outcomes from Phase 1 trial in uveal melanoma with liver metastases
TriSalus Life Sciences made a significant contribution to the Society of Immunotherapy for Cancer (SITC) 2023 Annual Meeting by revealing additional data from its Phase 1 PERIO-01 clinical trial of SD-101. The study, which centers on the treatment of liver metastases from uveal melanoma, utilized the company’s proprietary Pressure-Enabled Drug Delivery (PEDD) with TriNav Infusion […]